Harbor MedTech Inc. in Irvine raised $5 million in equity funding from three investors as part of an unfinished $8.5 million effort, a regulatory filing said.
The company develops tissue regeneration products from live sources—collagen protein, biologic substrates and xenografts—for chronic wounds, and hernia and joint repair.
The company has said its approach improves compatibility and speeds regeneration in tissue grafts and tissue growth.
Its first two products are Architect, which treats skin wounds, and EPMatrix, which treats soft-tissue injuries.
Prior to the most recent round the company raised $4.3 million in venture backing, Crunchbase said.
